Sign up to save your podcasts
Or
Share Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
View all episodes
By cancerGRACE - H. Jack West, MD
5
11 ratings
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
More shows like GRACEcast Lung Cancer Video
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Radiation Oncology Audio
0 Listeners
GRACEcast Radiation Oncology Video
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners